Myriad Genetics Reports Q3 2026 Results and Announces Prenatal Health Divestiture to Labcorp
Myriad Genetics (MYGN) reported third-quarter 2026 revenue of $202.7 million, driven by growth in its Cancer Care and Mental Health segments despite a significant 12% decline in Prenatal Health revenue. While the company posted a non-GAAP EPS loss of $0.11, management noted sequential improvements in laboratory efficiency and adjusted gross margins, which rose to 67.9%. A major strategic shift was announced via the all-cash sale of its Prenatal Health business to Labcorp for $210 million plus inventory. This divestiture is expected to significantly improve Myriad's financial profile by expanding gross margins by over 500 basis points and accelerating revenue growth post-transaction. Following these results, the company raised its full-year 2026 revenue guidance to a range of $780 million to $790 million.
Coverage
- Nutex Health GAAP EPS of $5.71 beats by $0.17, revenue of $217.6M beats by $2.78M
- Fulgent Genetics Non-GAAP EPS of -$0.09 beats by $0.56, revenue of $90.4M beats by $4.1M
- Myriad Genetics Reports Q3 2026 Results and Announces Prenatal Health Divestiture to Labcorp
- Myriad Genetics Outlines 2026 Revenue Guidance Following $210 Million Prenatal Health Divestiture